TW202112388A - Lotus seed coat extracts for preventing cell damage and the usage thereof - Google Patents
Lotus seed coat extracts for preventing cell damage and the usage thereof Download PDFInfo
- Publication number
- TW202112388A TW202112388A TW109106116A TW109106116A TW202112388A TW 202112388 A TW202112388 A TW 202112388A TW 109106116 A TW109106116 A TW 109106116A TW 109106116 A TW109106116 A TW 109106116A TW 202112388 A TW202112388 A TW 202112388A
- Authority
- TW
- Taiwan
- Prior art keywords
- lotus seed
- seed shell
- mixture
- extract
- shell extract
- Prior art date
Links
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 82
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 82
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title claims abstract description 82
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 230000005779 cell damage Effects 0.000 title claims abstract description 15
- 208000037887 cell injury Diseases 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 239000003642 reactive oxygen metabolite Substances 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000000605 extraction Methods 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 54
- 229960003180 glutathione Drugs 0.000 claims description 27
- 239000010903 husk Substances 0.000 claims description 15
- -1 polyphenol compound Chemical class 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 235000006708 antioxidants Nutrition 0.000 claims description 13
- 108010024636 Glutathione Proteins 0.000 claims description 11
- 235000013824 polyphenols Nutrition 0.000 claims description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- 229930003935 flavonoid Natural products 0.000 claims description 7
- 235000017173 flavonoids Nutrition 0.000 claims description 7
- 238000000265 homogenisation Methods 0.000 claims description 7
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 7
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 108010059820 Polygalacturonase Proteins 0.000 claims description 6
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 6
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 6
- 239000011573 trace mineral Substances 0.000 claims description 6
- 235000013619 trace mineral Nutrition 0.000 claims description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 3
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims description 3
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000005487 catechin Nutrition 0.000 claims description 3
- 229950001002 cianidanol Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 3
- 235000012734 epicatechin Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims description 3
- 235000008777 kaempferol Nutrition 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims description 3
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims description 3
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims description 2
- 235000007743 myricetin Nutrition 0.000 claims description 2
- 229940116852 myricetin Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 79
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 26
- 239000002609 medium Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000003064 anti-oxidating effect Effects 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000209447 Nelumbo Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 102000053529 human TNFSF11 Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000012451 post-reaction mixture Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Abstract
Description
本案係關於一種植物萃取物及其用途,特別係關於一種防止細胞傷害之蓮子殼萃取物及其用途。This case is about a plant extract and its use, especially a lotus seed shell extract for preventing cell damage and its use.
氧化壓力的產生是體內活性氧物質(Reactive oxygen species,簡稱ROS)和抗氧化劑防禦系統二者失衡的結果,大量的ROS生成會造成細胞中氧化壓力升高,進而造成細胞傷害或死亡,甚至導致許多疾病的形成。The production of oxidative stress is the result of the imbalance between the reactive oxygen species (ROS) and the antioxidant defense system in the body. A large amount of ROS production will increase the oxidative pressure in the cell, which will cause cell damage or death, and even lead to The formation of many diseases.
紫外線(Ultraviolet,簡稱UV)穿過大氣層後剩下主要的紫外線可依其波長再細分為UVA(波長320至400 nm)以及UVB(波長280至320 nm)。其中UVA的穿透力強,連一般透明玻璃都無法阻絕UVA的穿透,是日常生活中最容易曝曬到的紫外線,經由皮膚的吸收會對DNA造成傷害,或使細胞內ROS生成,進而導致細胞傷害或死亡,主要會造成雀斑及黑斑的惡化,並造成皮膚曬黑,也是造成皮膚老化的幫兇。Ultraviolet (Ultraviolet, referred to as UV) after passing through the atmosphere, the remaining main ultraviolet can be subdivided into UVA (wavelength 320 to 400 nm) and UVB (wavelength 280 to 320 nm) according to its wavelength. Among them, UVA has strong penetrating power, and even general transparent glass cannot block the penetration of UVA. It is the most easily exposed ultraviolet light in daily life. The absorption of the skin can cause damage to DNA or generate ROS in cells, which leads to Cell damage or death will mainly cause the deterioration of freckles and dark spots, and cause skin tanning. It is also an accomplice of skin aging.
有鑑於此,目前極需開發一種用於防止/避免細胞傷害之組合物,以使細胞具有抗氧化能力,且能防止其受紫外線傷害。In view of this, there is a great need to develop a composition for preventing/avoiding cell damage, so that the cells have antioxidant capacity and can prevent them from being damaged by ultraviolet rays.
有鑑於現有技術所面臨的問題,本案之一目的在提供一種用於防止細胞傷害之蓮子殼萃取物,其中蓮子殼萃取物係經由一種萃取方法而得,此種萃取方法包含將蓮子殼與水以1-5:10-30(1至5:10至30)之固液重量比,混和成為混和物,並將混和物均質後,在30-100℃進行反應0.5-3小時。In view of the problems faced by the prior art, one of the objectives of this case is to provide a lotus seed shell extract for preventing cell damage, wherein the lotus seed shell extract is obtained through an extraction method. This extraction method includes the lotus seed shell and water With a solid-liquid weight ratio of 1-5:10-30 (1 to 5:10 to 30), the mixture is mixed into a mixture, and the mixture is homogenized, and then reacted at 30-100°C for 0.5-3 hours.
在本案之一實施例中,混和物除了蓮子殼與水之外,更包含果膠酶,其中果膠酶佔混合物(進行反應前)的1wt%以下。In an embodiment of this case, the mixture contains pectinase in addition to the lotus seed shell and water, and the pectinase accounts for less than 1 wt% of the mixture (before the reaction).
在本案之一實施例中,萃取方法更包含將進行反應後的混合物冷卻至20-30℃;依序使用400目及5微米之濾網過濾;以及於45-70℃減壓濃縮。In an embodiment of this case, the extraction method further includes cooling the reacted mixture to 20-30°C; sequentially filtering with a 400 mesh and 5 micron filter; and concentrating under reduced pressure at 45-70°C.
在本案之一實施例中,蓮子殼與水之固液重量比為1:20。In an embodiment of this case, the solid-liquid weight ratio of lotus seed shell to water is 1:20.
在本案之一實施例中,混和物均質後,在80-90℃作用1小時。In an example of this case, after the mixture is homogenized, it is treated at 80-90°C for 1 hour.
在本案之一實施例中,混和物均質後,先在35-45℃作用1小時,再於80-90℃作用1小時。In an example of this case, after the mixture is homogenized, it is firstly treated at 35-45°C for 1 hour, and then at 80-90°C for 1 hour.
在本案之一實施例中,蓮子殼萃取物包含濃度為至少3毫克/毫升的多酚類化合物,較佳為包含濃度3-7毫克/毫升的多酚類化合物。In an embodiment of the present case, the lotus seed shell extract contains polyphenolic compounds at a concentration of at least 3 mg/ml, and preferably contains polyphenols at a concentration of 3-7 mg/ml.
在本案之一實施例中,蓮子殼萃取物包含多酚類化合物、類黃酮化合物及微量元素。In an embodiment of this case, the lotus seed shell extract contains polyphenol compounds, flavonoid compounds and trace elements.
在本案之一實施例中,多酚類化合物為兒茶素、表兒茶素、金絲桃苷或異槲皮苷。In an embodiment of this case, the polyphenol compound is catechin, epicatechin, hyperoside or isoquercitrin.
在本案之一實施例中,類黃酮化合物為槲皮素、楊梅黃酮或山奈酚;所述微量元素為鈣,鐵,鋅或磷。In an embodiment of this case, the flavonoid compound is quercetin, myricetin or kaempferol; the trace element is calcium, iron, zinc or phosphorus.
本案另提供一種關於將,蓮子殼萃取物用於製備抗氧化之組合物的用途。This case also provides a use of lotus seed husk extract to prepare an antioxidant composition.
在本案之一實施例中,抗氧化之組合物的抗氧化功效係透過增加細胞內穀胱甘肽(Glutathione,GSH)的含量,或減少細胞內活性氧物質(Reactive oxygen species,ROS)的含量而達成。In an embodiment of this case, the antioxidant effect of the antioxidant composition is through increasing the content of glutathione (Glutathione, GSH) in the cell, or reducing the content of reactive oxygen species (ROS) in the cell And reached.
本案另提供一種關於將蓮子殼萃取物用於製備防止細胞受紫外線傷害之組合物的用途。This case also provides a use of lotus seed shell extract to prepare a composition for preventing cells from being damaged by ultraviolet rays.
在本案之一實施例中,抗氧化之組合物與防止細胞受紫外線傷害之組合物之劑型為粉末、顆粒、液體、膠狀、膏狀、膠囊或錠劑。In an embodiment of this case, the dosage form of the anti-oxidant composition and the composition for preventing cell damage by ultraviolet rays is powder, granule, liquid, gel, paste, capsule or lozenge.
本案所提供之蓮子殼萃取物能有效增加細胞內穀胱甘肽(Glutathione,GSH)的含量,以及減少細胞內活性氧物質(Reactive oxygen species,ROS)的含量,進而防止/避免細胞受到氧化傷害,亦可有效抵抗紫外線所造成的細胞傷害。因此,本案之蓮子殼萃取物可用於製備抗氧化或防止細胞受紫外線傷害之組合物的用途。The lotus seed husk extract provided in this case can effectively increase the content of glutathione (Glutathione, GSH) in the cell, and reduce the content of reactive oxygen species (ROS) in the cell, thereby preventing/avoiding cell oxidative damage , Can also effectively resist cell damage caused by ultraviolet rays. Therefore, the lotus seed shell extract in this case can be used to prepare a composition for anti-oxidation or to prevent cells from being damaged by ultraviolet rays.
以下將配合圖式揭露本案之複數個實施例,為明確說明起見,許多實務上的細節將在以下敘述中一併說明。然而,這些實務上的細節不應用以限制本案。也就是說,在本案部分實施方式中,這些實務上的細節是非必要的。本文中所使用數值為近似值,所有實驗數據皆表示在20%的範圍內,較佳為在10%的範圍內,最佳為在5%的範圍內。In the following, a plurality of embodiments of this case will be disclosed in conjunction with the drawings. For the sake of clarity, many practical details will be described in the following description. However, these practical details should not be used to limit the case. In other words, in some implementations of this case, these practical details are unnecessary. The numerical values used herein are approximate values, and all experimental data are expressed in the range of 20%, preferably in the range of 10%, and most preferably in the range of 5%.
於本文中,除非內文中對於冠詞有所特別限定,否則「一」與「該」可泛指單一個或多個。可進一步理解的是,本文中所使用之「包含」、「包括」、「具有」及相似詞彙,指明其所記載的特徵、區域、整數、步驟、操作、元件與/或組件,但不排除其所述或額外的一個或多個其它特徵、區域、整數、步驟、操作、元件、組件,與/或其中之群組。In this article, unless the article is specifically limited in the context, "一" and "the" can generally refer to one or more. It can be further understood that the terms "include", "include", "have" and similar words used in this text indicate the recorded features, regions, integers, steps, operations, elements and/or components, but do not exclude The described or additional one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.
經由前述內容,可得知紫外線經由皮膚吸收會對DNA造成傷害,大量的ROS生成也會使細胞中氧化壓力升高,進而導致細胞傷害或死亡,造成許多疾病的產生。From the foregoing, it can be known that the absorption of ultraviolet rays through the skin will cause damage to DNA, and a large amount of ROS production will also increase the oxidative pressure in the cells, which will lead to cell damage or death, and cause many diseases.
有鑑於此,本案提供一種蓮子殼萃取物,可用於防止細胞受紫外線傷害,並具有抗氧化之功能,能有效抑制ROS生成,降低細胞內氧化壓力,進而保護細胞不受傷害。In view of this, this case provides a lotus seed shell extract, which can be used to prevent cells from being damaged by ultraviolet rays, and has the function of anti-oxidation, which can effectively inhibit the generation of ROS, reduce the oxidative pressure in the cells, and protect the cells from damage.
以下將詳細說明本案蓮子殼萃取物之萃取方法,與其抗氧化、抗紫外線功能的測試,以證實本案之蓮子殼萃取物確有保護細胞不受紫外線傷害及抗氧化的能力。The following will explain in detail the extraction method of the lotus husk extract in this case, and its anti-oxidation and anti-ultraviolet function tests to verify that the lotus husk extract in this case does have the ability to protect cells from UV damage and anti-oxidation.
本案使用穀胱甘肽(Glutathione,GSH)及活性氧物質(Reactive oxygen species,ROS)作為抗氧化功能的指標。GSH是由麩胺酸、胱胺酸和甘胺酸所組成的三胜肽,其硫醇基(-SH)與氧化還原相關;主要功能為細胞內生性抗氧化的防禦,可以對抗ROS的氧化傷害,因此,若細胞內的GSH的含量升高,則會增加細胞內氧化還原的能力,使細胞具有較好的抗氧化功能;另外,若細胞內ROS的生成下降,則會降低細胞內的氧化壓力,亦可使細胞具有較好的抗氧化功效。In this case, glutathione (Glutathione, GSH) and reactive oxygen species (ROS) were used as indicators of antioxidant function. GSH is a tripeptide composed of glutamine, cystine and glycine, and its thiol group (-SH) is related to redox; its main function is the defense of cellular endogenous antioxidants, which can resist the oxidation of ROS Therefore, if the content of GSH in the cell is increased, it will increase the ability of redox in the cell, so that the cell has a better antioxidant function; in addition, if the production of ROS in the cell decreases, it will reduce the intracellular Oxidative stress can also make cells have a better antioxidant effect.
實施例一:蓮子殼萃取物製備流程A 1.清洗蓮子殼,供後續萃取用;蓮子殼係來自於蓮屬(Nelumbo )植物種子之外殼。 2.將洗淨後的蓮子殼與水以1-5:10-30之固液重量比混和得到蓮子殼與水的混合液,蓮子殼與水的混合液於30-100℃進行均質作用0.5-3小時;在一些實施例中,所述的水可為逆滲透(RO)水;在一些實施例中,蓮子殼與水以1:20之固液重量比混和,混和後得到之蓮子殼與水的混合液於80-90℃進行均質作用1小時。 3.將進行均質作用後的蓮子殼與水的混合液冷卻至室溫(在一些實施例中,約20-30℃,例如可為25℃)。 4.依序使用400目(mesh)及5微米之濾網過濾步驟3所得到的蓮子殼與水的混合液。 5.將步驟4得到的過濾液於45-70℃減壓濃縮,例如可為在60±5℃進行減壓濃縮,得到蓮子殼萃取物。在一些實施例中,萃取出之蓮子殼萃取物包含多酚類化合物(例如兒茶素、表兒茶素、金絲桃苷或異槲皮苷等)、類黃酮化合物(例如槲皮素、楊梅黃酮或山奈酚等)及微量元素(例如鈣、鐵、鋅或磷等佔人類總質量0.02%以下元素)。在一些實施例中,蓮子殼萃取物中的多酚類化合物之濃度為3毫克/毫升(mg/mL)以上,或可為3-7毫克/毫升;在一些實施例中,蓮子殼萃取物中的多酚類化合物之濃度為5.9毫克/毫升。Example 1: Preparation process of lotus seed shell extract A 1. Wash the lotus seed shell for subsequent extraction; the lotus seed shell is derived from the outer shell of the Nelumbo plant seed. 2. Mix the washed lotus shell and water at a solid-liquid weight ratio of 1-5:10-30 to obtain a mixture of lotus shell and water. The mixture of lotus shell and water is homogenized at 30-100°C for 0.5 -3 hours; in some embodiments, the water may be reverse osmosis (RO) water; in some embodiments, lotus seed shells and water are mixed at a solid-to-liquid weight ratio of 1:20, and the lotus seed shells obtained after mixing The mixture with water is homogenized at 80-90°C for 1 hour. 3. Cool the mixture of lotus seed shell and water after homogenization to room temperature (in some embodiments, about 20-30° C., for example, 25° C.). 4. Sequentially use 400 mesh and 5 micron filters to filter the lotus seed shell and water mixture obtained in step 3. 5. The filtrate obtained in step 4 is concentrated under reduced pressure at 45-70°C, for example, concentrated under reduced pressure at 60±5°C to obtain the lotus seed shell extract. In some embodiments, the extracted lotus seed shell extract contains polyphenolic compounds (such as catechin, epicatechin, hyperoside or isoquercitrin, etc.), flavonoid compounds (such as quercetin, quercetin, etc.) Bayberry flavonoids or kaempferol, etc.) and trace elements (such as calcium, iron, zinc, or phosphorus, which account for less than 0.02% of the total human mass). In some embodiments, the concentration of polyphenol compounds in the lotus husk extract is 3 milligrams/ml (mg/mL) or more, or can be 3-7 mg/ml; in some embodiments, the lotus husk extract The concentration of polyphenolic compounds in 5.9 mg/ml.
實施例二:蓮子殼萃取物製備流程B 1.清洗蓮子殼,供後續萃取用;蓮子殼係來自於蓮屬(Nelumbo )植物種子之外殼。 2.將洗淨後的蓮子殼與水以1-5:10-30之固液重量比進行混和,並進一步添加果膠酶(購自恒洲實業股份有限公司,Viscozyme L)(添加後,果膠酶不超過整體蓮子殼與水的混合液的1wt%),於35-45℃進行均質作用1小時,再於80-90℃進行均質作用1小時;在一些實施例中,蓮子殼與水係以1:20之固液重量比混和後,先於35-45℃進行均質作用1小時,再於80-90℃進行均質作用1小時;所述水可為逆滲透(RO)水。 3.將步驟2所得到之反應後混合液冷卻至室溫(在一些實施例中,約20-30℃,例如可為25℃)。 4.依序使用400目(mesh)及5微米之濾網過濾步驟3所得到的混合液。 5.將步驟4得到的過濾液於45-70℃減壓濃縮,得到蓮子殼萃取物。在一些實施例中,可為在55-65℃進行減壓濃縮。在一些實施例中,萃取出之蓮子殼萃取物包含多酚類化合物、類黃酮化合物及微量元素。在一些實施例中,蓮子殼萃取物中的多酚類化合物之濃度為3毫克/毫升(mg/mL)以上,或可為3-7毫克/毫升;在一些實施例中,蓮子殼萃取物中的多酚類化合物之濃度為5.9毫克/毫升。Example 2: Preparation process B of lotus seed shell extract 1. Wash the lotus seed shell for subsequent extraction; the lotus seed shell is derived from the shell of the Nelumbo plant seed. 2. Mix the washed lotus seed shell with water at a solid-liquid weight ratio of 1-5:10-30, and further add pectinase (purchased from Hengzhou Industrial Co., Ltd., Viscozyme L) (after adding, Pectinase does not exceed 1wt% of the mixture of whole lotus seed shell and water), homogenize at 35-45°C for 1 hour, and then homogenize at 80-90°C for 1 hour; in some embodiments, lotus seed shell and water After the water system is mixed with a solid-liquid weight ratio of 1:20, homogenization is performed at 35-45°C for 1 hour, and then at 80-90°C for 1 hour; the water can be reverse osmosis (RO) water. 3. Cool the post-reaction mixture obtained in step 2 to room temperature (in some embodiments, about 20-30°C, for example, 25°C). 4. Sequentially use 400 mesh and 5 micron filters to filter the mixed solution obtained in step 3. 5. The filtrate obtained in step 4 is concentrated under reduced pressure at 45-70°C to obtain the lotus seed shell extract. In some embodiments, it may be concentrated under reduced pressure at 55-65°C. In some embodiments, the extracted lotus seed shell extract contains polyphenol compounds, flavonoid compounds and trace elements. In some embodiments, the concentration of polyphenol compounds in the lotus husk extract is 3 milligrams/ml (mg/mL) or more, or can be 3-7 mg/ml; in some embodiments, the lotus husk extract The concentration of polyphenolic compounds in 5.9 mg/ml.
實施例三:評估細胞抗氧化功效-周邊血單核球細胞之GSH含量檢測 A. 實驗材料 1. 細胞株:人類周邊血單核球細胞(human peripheral blood mononuclear cell,hPBMC)。 2. 培養基:破骨細胞分化培養基(osteoclast differentiation medium),此破骨細胞分化培養基由添加了10%胎牛血清(fetal bovine serum,FBS)、1x 青黴素/鏈黴素(Penicillin/Streptomycin)、人類核因子κ-B配體受體致活劑 (human RANKL)(40 ng / mL)及人類聚落刺激因子(human M-CSF)(25 ng / mL)的α-最小必須培養基(α-minimum essential medium,α-MEM)所組成。 3. GSH檢測試劑(購自abcam,型號Ab112132)。 B. 實驗步驟 1.於6孔培養盤中,每孔培養基中植入2x105 個人類周邊血單核球細胞(於後方步驟中將略稱為細胞)。 2.於37℃培養24小時。 3.將細胞分為二組:第一組為空白組(Mock);第二組(實驗組)則加入蓮子殼萃取物,使加入蓮子殼萃取物後,整體溶液中的蓮子殼萃取物濃度為0.0625 mg/mL;接著將兩組細胞於37℃培養24小時。 4.收集細胞。 5.用磷酸鹽緩衝生理鹽水(Phosphate-Buffered Saline,PBS)(購自Gibco)沖洗一次。 6.重懸浮細胞(Resuspend cells)於1毫升的PBS。 7.以GSH試劑(1:1000)將細胞染色15分鐘。 8.用PBS沖洗一次。 9.重懸浮細胞(Resuspend cells)於200微升的PBS。 10.通過流式細胞儀(購自BD Accuri,型號C6 Plus)分析相對的螢光異硫氰酸鹽(FITC)訊號。 11.偵測出之數值以微軟EXCEL軟體,利用Student t檢定分析數值間的統計顯著性,其結果如圖1所示。其中,相較於空白組,***表示p >0.001。Example 3: Evaluation of Cell Antioxidant Efficacy-Detection of GSH Content of Peripheral Blood Mononuclear Cells A. Experimental Materials 1. Cell line: human peripheral blood mononuclear cell (hPBMC). 2. Medium: Osteoclast differentiation medium (osteoclast differentiation medium), which is supplemented with 10% fetal bovine serum (FBS), 1x penicillin/streptomycin (Penicillin/Streptomycin), human Nuclear factor κ-B ligand receptor activator (human RANKL) (40 ng/mL) and human colony stimulating factor (human M-CSF) (25 ng/mL) α-minimum essential medium (α-minimum essential) medium, α-MEM). 3. GSH detection reagent (purchased from abcam, model Ab112132). B. Experimental steps 1. In a 6-well culture dish, implant 2x10 5 human peripheral blood mononuclear cells (abbreviated as cells in the following steps) into each well of culture medium. 2. Incubate at 37°C for 24 hours. 3. Divide the cells into two groups: the first group is the blank group (Mock); the second group (experimental group) is added with lotus seed shell extract, so that after adding the lotus seed shell extract, the concentration of the lotus seed shell extract in the overall solution It was 0.0625 mg/mL; then the two groups of cells were cultured at 37℃ for 24 hours. 4. Collect the cells. 5. Rinse once with Phosphate-Buffered Saline (PBS) (purchased from Gibco). 6. Resuspend cells in 1 ml of PBS. 7. Stain the cells with GSH reagent (1:1000) for 15 minutes. 8. Rinse once with PBS. 9. Resuspend cells in 200 microliters of PBS. 10. Analyze the relative fluorescent isothiocyanate (FITC) signal by flow cytometry (purchased from BD Accuri, model C6 Plus). 11. The detected values are analyzed by the Microsoft EXCEL software using Student t test to analyze the statistical significance between the values. The results are shown in Figure 1. Among them, compared with the blank group, *** means p >0.001.
由圖1結果可知,有加入蓮子殼萃取物的第二組(實驗組)細胞,可明顯增加其GSH含量,使其相對GSH含量(relative GSH content)為第一組(空白組)細胞的3.5倍。GSH是由麩胺酸、胱胺酸和甘胺酸所組成的三胜肽,其硫醇基(-SH)與氧化還原相關,主要功能為細胞內生性抗氧化的防禦,可以對抗ROS的氧化傷害。因此,由圖1的結果亦可證實,添加本案實施例一或實施例二萃取而得之蓮子殼萃取物,確實可提升細胞中GSH含量,增加細胞內氧化還原的能力,以達到細胞抗氧化的功效。From the results in Figure 1, it can be seen that the second group of cells (experimental group) added with lotus seed shell extract can significantly increase their GSH content, making the relative GSH content (relative GSH content) 3.5 of that of the first group (blank group). Times. GSH is a tripeptide composed of glutamine, cystine and glycine. Its thiol group (-SH) is related to redox, and its main function is the defense of cellular endogenous antioxidants, which can resist the oxidation of ROS. hurt. Therefore, the results in Fig. 1 can also confirm that adding the lotus seed shell extract extracted from Example 1 or Example 2 of this case can indeed increase the GSH content in cells and increase the ability of redox in cells to achieve cellular anti-oxidation. The effect of.
實例四:評估細胞抗氧化功效-周邊血單核球細胞的ROS傷害檢測 A. 實驗材料及器材 1. 人類周邊血單核球細胞(human peripheral blood mononuclear cell,hPBMC)。 2. 培養基:X-VIVO™ 10 培養基(購自Lonza/產品編號:Cat#04-380Q)。 3. 磷酸鹽緩衝生理鹽水(PBS)(購自Gibco)。 4. 2',7'-二氯螢光素二乙酸酯(2’,7’-Dichlorofluorescin diacetate,DCFH-DA)保存液(stock solution):將DCFH-DA(購自Sigma-Aldrich,產品型號SI-D6883-50MG)保存於二甲基亞碸(Dimethyl sulfoxide,DMSO,購自Sigma-Aldrich)中,濃度為5 mg/mL。 5. 過氧化氫(H2 O2 )(購自Sigma-Aldrich,30wt%之水溶液)。 6. 流式細胞儀(購自BD Accuri)。 B. 實驗步驟 1.於6孔培養盤中,每孔植入含有2x105 個人類周邊血單核球細胞(於後方步驟中將略稱為細胞)的2毫升培養基。 2.於37℃培養24小時。 3.移除培養基。 4.將細胞分為三組:第一組為空白組(Mock);第二組(實驗組)加入過氧化氫,使加入過氧化氫後,整體溶液中的過氧化氫濃度為1 mM;第三組(實驗組)加入過氧化氫與蓮子殼萃取物,使過氧化氫於整體溶液中的濃度為1 mM,而蓮子殼萃取物於整體溶液中的濃度為0.03125 mg/mL;接著將三組細胞於37℃培養1小時。 5.加入5微克/毫升(μg/ mL)DCFH-DA保存液於每孔中,再於37℃下放置15分鐘使其進一步反應。 6.在37℃下加入過氧化氫於細胞(加入後,溶液整體中的過氧化氫濃度為1 mM),並靜置1小時。 7.以1毫升1X PBS清洗每個孔兩次。 8.加入200微升胰蛋白酶(購自Gibco,型號15400-054),於黑暗中反應5分鐘。 9.將帶有細胞的培養基收集到1.5毫升試管中,並以400xg離心10分鐘。 10.除去上清液,並用1X PBS洗滌一次。 11.以400xg離心10分鐘。 12.除去上清液,並用1毫升1X PBS重懸浮細胞沉澱(resuspend the cell pellet)。 13.以流式細胞儀,分別於激發波長(450-490 nm)與發射波長(510-550 nm)下偵測DCFH-DA的螢光訊號。 14.偵測出之數值以微軟EXCEL軟體,利用Student t檢定分析數值間的統計顯著性,其結果如圖2所示。其中,第二組(過氧化氫)相較於第一組(空白組),###表示p >0.001;第三組(過氧化氫+蓮子殼萃取物)相較於第二組(過氧化氫),***表示p >0.001。Example 4: Evaluation of cellular anti-oxidation efficacy-detection of ROS damage to peripheral blood mononuclear cells A. Experimental materials and equipment 1. Human peripheral blood mononuclear cells (hPBMC). 2. Medium: X-VIVO™ 10 medium (purchased from Lonza/product number: Cat#04-380Q). 3. Phosphate buffered saline (PBS) (purchased from Gibco). 4. 2',7'-Dichlorofluorescin diacetate (2',7'-Dichlorofluorescin diacetate, DCFH-DA) stock solution (stock solution): DCFH-DA (purchased from Sigma-Aldrich, product Model SI-D6883-50MG) is stored in dimethyl sulfoxide (DMSO, purchased from Sigma-Aldrich) at a concentration of 5 mg/mL. 5. Hydrogen peroxide (H 2 O 2 ) (purchased from Sigma-Aldrich, 30wt% aqueous solution). 6. Flow cytometer (purchased from BD Accuri). B. Experimental steps 1. In a 6-well culture dish, implant 2 ml of culture medium containing 2x10 5 human peripheral blood mononuclear cells (abbreviated as cells in the following steps) in each well. 2. Incubate at 37°C for 24 hours. 3. Remove the medium. 4. Divide the cells into three groups: the first group is a blank group (Mock); the second group (experimental group) is added with hydrogen peroxide, so that after adding hydrogen peroxide, the concentration of hydrogen peroxide in the overall solution is 1 mM; The third group (experimental group) added hydrogen peroxide and lotus husk extract so that the concentration of hydrogen peroxide in the overall solution was 1 mM, and the concentration of lotus husk extract in the overall solution was 0.03125 mg/mL; The three groups of cells were cultured at 37°C for 1 hour. 5. Add 5 μg/ml (μg/mL) DCFH-DA preservation solution to each well, and then place it at 37°C for 15 minutes for further reaction. 6. Add hydrogen peroxide to the cells at 37°C (after adding, the concentration of hydrogen peroxide in the whole solution is 1 mM), and let stand for 1 hour. 7. Wash each well twice with 1 ml of 1X PBS. 8. Add 200 μl trypsin (purchased from Gibco, model 15400-054), and react for 5 minutes in the dark. 9. Collect the medium with the cells in a 1.5 ml test tube and centrifuge at 400xg for 10 minutes. 10. Remove the supernatant and wash once with 1X PBS. 11. Centrifuge at 400xg for 10 minutes. 12. Remove the supernatant and resuspend the cell pellet with 1 ml of 1X PBS. 13. Use a flow cytometer to detect the fluorescent signal of DCFH-DA at the excitation wavelength (450-490 nm) and emission wavelength (510-550 nm). 14. The detected values are analyzed with the use of Microsoft EXCEL software and Student t test to analyze the statistical significance between the values. The results are shown in Figure 2. Among them, the second group (hydrogen peroxide) is compared with the first group (blank group), ### indicates p >0.001; the third group (hydrogen peroxide + lotus seed shell extract) is compared with the second group (over Hydrogen oxide), *** means p >0.001.
由圖2結果可知,若單獨提供過氧化氫予細胞(第二組細胞),其相對ROS生成量(relative ROS production)為空白組(第一組細胞)的1.6倍,由此可知,過氧化氫會增加細胞中ROS的生成;然而,若在給予細胞過氧化氫時,一同給予本案實施例一或實施例二所述之蓮子殼萃取物(第三組細胞),即可發現其相對ROS的生成量則為空白組(第一組細胞)的0.8倍,有效減少了過氧化氫所促進的相對ROS生成量,甚至少於空白組(第一組)細胞中ROS的生成量,由此可知,本案所提供之蓮子殼萃取物,可降低細胞內ROS的生成,降低氧化壓力,使細胞具有抗氧化功能。It can be seen from the results in Figure 2 that if hydrogen peroxide is provided to the cells (the second group of cells) alone, the relative ROS production (relative ROS production) is 1.6 times that of the blank group (the first group of cells). Hydrogen can increase the production of ROS in cells; however, if the lotus seed shell extract (third group of cells) described in Example 1 or Example 2 is administered together with the hydrogen peroxide to the cells, it can be found to be relative to ROS. The amount of ROS produced in the blank group (the first group of cells) was 0.8 times that of the blank group (the first group of cells), effectively reducing the relative ROS production promoted by hydrogen peroxide, and even less than the amount of ROS produced in the blank group (the first group). It can be seen that the lotus seed shell extract provided in this case can reduce the generation of ROS in cells, reduce oxidative stress, and make cells have antioxidant functions.
實施例五:抵抗及防禦紫外線能力 A. 實驗材料及器材 1.細胞株:人類皮膚纖維母細胞(CCD-966sk)(ATCC,CRL-1881)。 2.培養基:最小必須培養基(minimum essential medium,MEM),其含有10% FBS、1%青黴素/鏈黴素及1 mM丙酮酸鈉(購自Gibco)。 3.將3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴鹽(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,MTT)(AMERSCO 0793-5G)溶於PBS中,配置成濃度為4 mg/mL之溶液。 4.DMSO(ECHO / DA1101-000000-72EC)。 5.酵素免疫分析儀(ELISA reader)(購自BioTek)。 6.紫外線照射室(Ultraviolet radiation chamber)(購自Vilber)。 B. 實驗步驟 1.於96孔培養盤中,每孔植入含有5x103 個細胞的200微升(μL)培養基。 2.於37℃培養24小時。 3.在不擾動貼附細胞的情況下去除培養基。 4.將細胞分為三組,第一組為空白組(Mock),不投以紫外線;第二組(實驗組)只投以紫外線(較佳為UVA)照射;第三組(實驗組)則先加入蓮子殼萃取物,使其蓮子殼萃取物最終濃度為0.125 mg/mL,再投以紫外線(較佳為UVA)照射;前述所稱之「投以紫外線照射」係利用紫外線照射室將上述培養盤照射15J/cm2 的紫外線1小時,較佳地為照射15 J/cm2 的UVA 1小時,此時會造成LD50(50%的致死劑量),代表導致半數細胞死亡之電離輻射(ionizing radiation)劑量。 5.接著將三組細胞於37℃培養24小時。 6.每孔添加15微升的MTT溶液,然後於37℃培養4小時。 7.去除培養基後,每孔添加50微升DMSO以溶解甲䐶(formazan)結晶。 8.將培養盤放於震盪器上培養10分鐘。 9.測量波長570nm之吸光度(O.D值)。 10.細胞存活率之MTT分析:細胞存活率(%)=(實驗組O.D值/空白組O.D值)×100%,前述「實驗組」指的是實施例五中的第二、三組細胞,而「空白組」指的是實施例五中的第一組細胞。 11.以微軟EXCEL軟體,利用Student t檢定分析數值間的統計顯著性,其結果如圖3所示。其中,第二組(紫外線,較佳為UVA)相較於第一組(空白組),##表示p >0.01;第三組(紫外線(較佳為UVA)+蓮子殼萃取物)相較於第二組(紫外線,較佳為UVA),***表示p >0.001。Example 5: Ability to resist and defend against ultraviolet rays A. Experimental materials and equipment 1. Cell line: Human skin fibroblasts (CCD-966sk) (ATCC, CRL-1881). 2. Medium: minimum essential medium (MEM), which contains 10% FBS, 1% penicillin/streptomycin and 1 mM sodium pyruvate (purchased from Gibco). 3. The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (3-(4,5-Dimethylthiazol-2-yl)-2,5 -diphenyltetrazolium bromide, MTT) (AMERSCO 0793-5G) is dissolved in PBS, and the concentration is 4 mg/mL. 4. DMSO (ECHO / DA1101-000000-72EC). 5. Enzyme immunoassay (ELISA reader) (purchased from BioTek). 6. Ultraviolet radiation chamber (purchased from Vilber). B. Procedure 1. 96-well culture plate, each well containing 5x10 3 implanted cells 200-microliter ([mu] L) medium. 2. Incubate at 37°C for 24 hours. 3. Remove the culture medium without disturbing the attached cells. 4. Divide the cells into three groups, the first group is a blank group (Mock), and no ultraviolet light is applied; the second group (experimental group) is only irradiated with ultraviolet light (preferably UVA); the third group (experimental group) The lotus seed shell extract is added first to make the final concentration of the lotus seed shell extract 0.125 mg/mL, and then irradiated with ultraviolet rays (preferably UVA); The above-mentioned culture plate is irradiated with 15 J/cm 2 of ultraviolet light for 1 hour, preferably 15 J/cm 2 of UVA for 1 hour. At this time, it will cause LD50 (50% lethal dose), which represents ionizing radiation that causes half of the cells to die ( ionizing radiation) dose. 5. Then the three groups of cells were cultured at 37°C for 24 hours. 6. Add 15 microliters of MTT solution to each well, and then incubate at 37°C for 4 hours. 7. After removing the medium, add 50 microliters of DMSO to each well to dissolve the formazan crystals. 8. Put the culture plate on the shaker and incubate for 10 minutes. 9. Measure the absorbance (OD value) at a wavelength of 570nm. 10. MTT analysis of cell survival rate: cell survival rate (%) = (experimental group OD value / blank group OD value) × 100%, the aforementioned "experimental group" refers to the second and third groups of cells in Example 5 , And the "blank group" refers to the first group of cells in Example 5. 11. Using Microsoft EXCEL software, the Student t test was used to analyze the statistical significance between the values. The results are shown in Figure 3. Among them, the second group (ultraviolet rays, preferably UVA) is compared with the first group (blank group), ## means p >0.01; the third group (ultraviolet rays (preferably UVA) + lotus seed shell extract) is compared In the second group (ultraviolet rays, preferably UVA), *** means p >0.001.
紫外線對細胞所造成的傷害大部分來自於UVA(約占紫外線的95%),且UVA波長較其他UV長,介於320-400 nm,可穿透表皮,傷害真皮層細胞,紫外線亦可使細胞產生ROS,進而增加細胞內的氧化壓力,促使皮膚老化、鬆弛及黑色素沉澱。Most of the damage caused by ultraviolet rays to cells comes from UVA (about 95% of ultraviolet rays), and the wavelength of UVA is longer than other UV, between 320-400 nm, which can penetrate the epidermis and damage the cells of the dermis. The cells produce ROS, which in turn increases the oxidative pressure in the cells, which promotes skin aging, relaxation and melanin precipitation.
因此,由圖3結果可知,將細胞只投以紫外線(較佳為UVA)照射(第二組細胞)的情況下,其細胞存活率為96.57%,由此可知紫外線(較佳為UVA)會造成細胞傷害或死亡;然而,若對細胞投以紫外線(較佳為UVA)照射時,一同給予本案實施例一或二所述之蓮子殼萃取物(第三組細胞),即可發現其細胞存活率為127.77%,有效改善了紫外線(較佳為UVA)所導致的細胞傷害或死亡,且有添加本案之蓮子殼萃取物之細胞,其細胞存活率甚至高於空白組(第一組細胞),由此可知,本案所提供之蓮子殼萃取物,可抵抗紫外線(尤其是UVA)造成的細胞傷害,及防禦輻射對細胞造成的危害,進而避免皮膚細胞產生老化、鬆弛及黑色素沉澱等問題。Therefore, it can be seen from the results in Fig. 3 that when the cells are irradiated with only ultraviolet light (preferably UVA) (the second group of cells), the cell survival rate is 96.57%. It can be seen that ultraviolet light (preferably UVA) will Causes cell damage or death; however, if the cells are irradiated with ultraviolet rays (preferably UVA), the lotus seed shell extract (the third group of cells) described in Example 1 or 2 of this case is administered together, and the cells can be found The survival rate was 127.77%, which effectively improved the damage or death of cells caused by ultraviolet rays (preferably UVA), and the cell survival rate of the cells added with the lotus seed shell extract in this case was even higher than that of the blank group (the first group of cells) ), it can be seen that the lotus seed shell extract provided in this case can resist cell damage caused by ultraviolet rays (especially UVA) and prevent radiation damage to cells, thereby avoiding skin cells from aging, relaxation and melanin precipitation. .
由上述本案實施方式或實施例可知,本案提供之一種蓮子殼萃取物及其萃取方法、用途,可透過增加細胞內穀胱甘肽(Glutathione,GSH)的含量,或/及減少細胞內活性氧物質(reactive oxygen species,ROS)的含量,來達成細胞抗氧化的功能;亦能使細胞(尤其是皮膚細胞)抵抗或防禦紫外線(尤其是UVA)所造成的傷害,使其免於老化、鬆弛及黑色素沉澱等問題。It can be seen from the above implementations or examples of this case that the lotus seed shell extract and its extraction method and application provided in this case can increase the content of glutathione (Glutathione, GSH) in the cell, or/and reduce the reactive oxygen species in the cell. The content of substances (reactive oxygen species, ROS) to achieve the function of cellular anti-oxidation; it can also make cells (especially skin cells) resist or defend against damage caused by ultraviolet rays (especially UVA), so as to prevent aging and relaxation And melanin precipitation and other issues.
此外,本案所述含有蓮子殼萃取物之組合物,亦可進一步包含所屬技術領域通常知識者所熟知之載劑或其他輔劑;而所述組合物之劑型,可為但不限於粉末、顆粒、液體、膠狀、膏狀、膠囊或錠劑;且所述組合物亦可添加於食品、保健食品或膳食補充品中,或進一步應用於美容、保養品或面膜等產品中。In addition, the composition containing lotus seed husk extract described in this case may further include carriers or other adjuvants well known to those skilled in the art; and the dosage form of the composition may be, but not limited to, powders and granules. , Liquid, gel, paste, capsule or lozenge; and the composition can also be added to foods, health foods or dietary supplements, or further applied to products such as beauty, skin care products or facial masks.
前述內容已概括數個實施方式/實施例之特徵。彼等熟習此項技術者應瞭解,本揭露可易於用作設計或修正其他製程及結構之基礎,以實現與本案介紹之實施方式相同的目的及/或達到與其相同的優勢。彼等熟習此項技術者亦應瞭解,同等構造不脫離本揭露之精神及範疇,及可在不脫離本揭露精神及範疇之情況下在本案中進行多種變更、取代及更動。The foregoing content has summarized the characteristics of several implementations/examples. Those who are familiar with this technology should understand that this disclosure can be easily used as a basis for designing or modifying other processes and structures to achieve the same purpose and/or the same advantages as the implementation described in this case. Those who are familiar with this technology should also understand that the equivalent structure does not deviate from the spirit and scope of this disclosure, and various changes, substitutions and alterations can be made in this case without departing from the spirit and scope of this disclosure.
無。no.
以下將配合圖式進一步說明本案的實施方式,下述所列舉的實施例係用以闡明本案之案特點及應用,而非以限定本案之範圍,任何熟習相關技術者,在不脫離本案之精神和範圍內,當可做些許更動與潤飾,因此本案之保護範圍當視後附之申請專利範圍所界定者為準。 圖1顯示本案一實施例中蓮子殼萃取物對細胞內穀胱甘肽(Glutathione,GSH)含量的影響。 圖2顯示本案一實施例中蓮子殼萃取物對細胞內活性氧物質(Reactive oxygen species,ROS)生成的影響。 圖3顯示本案一實施例中蓮子殼萃取物對細胞抵抗/防禦紫外線的影響。The following will further illustrate the implementation of this case in conjunction with the drawings. The following examples are used to illustrate the characteristics and applications of the case, not to limit the scope of the case. Anyone familiar with the relevant technology will not deviate from the spirit of the case. Within the scope and scope, some changes and modifications can be made. Therefore, the scope of protection in this case shall be subject to the scope of the attached patent application. Figure 1 shows the effect of lotus seed shell extract on the content of Glutathione (GSH) in cells in an example of this case. Figure 2 shows the effect of lotus seed shell extract on the production of reactive oxygen species (ROS) in cells in an example of this case. Figure 3 shows the effect of lotus seed shell extract on cell resistance/defense against ultraviolet rays in an example of this case.
無。no.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020033008A JP2021054784A (en) | 2019-09-26 | 2020-02-28 | Lotus seed shell extract and its uses to prevent cytotoxicity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962906126P | 2019-09-26 | 2019-09-26 | |
US62/906,126 | 2019-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202112388A true TW202112388A (en) | 2021-04-01 |
Family
ID=75040797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109106116A TW202112388A (en) | 2019-09-26 | 2020-02-25 | Lotus seed coat extracts for preventing cell damage and the usage thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112546095A (en) |
TW (1) | TW202112388A (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201521782A (en) * | 2013-12-03 | 2015-06-16 | Guang Ding Biotech Company | Use of cirsium japonicum var. austral extracts for anti-oxidation |
-
2020
- 2020-02-25 TW TW109106116A patent/TW202112388A/en unknown
- 2020-03-25 CN CN202010217844.7A patent/CN112546095A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN112546095A (en) | 2021-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bagchi et al. | Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula | |
Malinowska | Effect of flavonoids content on antioxidant activity of commercial cosmetic plant extracts | |
EP4039261A2 (en) | Plant extract composition and use thereof for reducing uv damage | |
KR101402550B1 (en) | Antioxidizing Functional Cosmetic Compositions for Containing Extracted/Fermented Dendropanax morbifera Products and Functional Cosmetics Produced Thereby | |
JPH09241637A (en) | Composition for removing active oxygen free radical and removal thereof | |
Aidoo et al. | Protective effect of bergapten against human erythrocyte hemolysis and protein denaturation in vitro | |
CN108567632B (en) | Application of tea tree callus extract in skin care | |
Li et al. | Amauroderma rugosum protects PC12 cells against 6-OHDA-induced neurotoxicity through antioxidant and antiapoptotic effects | |
JP2015513395A (en) | Compositions and methods for quenching free radicals and modulating inflammation | |
CN114344352A (en) | Composition with effect of resisting advanced glycosylation end products and application thereof | |
Peoples et al. | Skin rejuvenating effect of consciousness energy healing treatment based herbomineral formulation | |
KR101558182B1 (en) | Skin External Composition Containing Extracts of Chrysanthemum indicum var. albescens | |
TW202112388A (en) | Lotus seed coat extracts for preventing cell damage and the usage thereof | |
KR101558184B1 (en) | Anti-aging composition containing red-grape-leaf extract berrylike mixtures and selenium | |
JP2011184357A (en) | Singlet oxygen eliminator, and skin preparation for external use and cosmetic by using singlet oxygen eliminator | |
CN108066217B (en) | Antioxidant composition and preparation method and application thereof | |
Kassem et al. | Dietary gum Arabic supplementation alter plasma and tissue antioxidant and free radical scavenging activities in Sprague Dawley male rats | |
Karthishwaran et al. | Assessment of the antioxidant potential of Pergularia daemia (Forsk.) extract in vitro and in vivo experiments on hamster buccal pouch carcinogenesis | |
EP3758799B1 (en) | Composition for the prevention and treatment of skin damages caused by photo-exposure | |
JP2021054784A (en) | Lotus seed shell extract and its uses to prevent cytotoxicity | |
Musthafa et al. | Ameliorative efficacy of bioencapsulated Chironomous larvae with Shilajit on Zebrafish (Danio rerio) exposed to Ionizing radiation | |
KR20140052127A (en) | Skin wrinkle improving cosmetic compositions containing enzymaticallly hydrolyzed apple extract | |
KR102066435B1 (en) | Method for manufacturing collagen using olive and olive collagen manufactured by using the same and cosmetic compositions comprising the olive collagen | |
KR20100090533A (en) | Method of extracting for sea silt extract and whitening functional cosmetic composition containing the extract | |
CN111205259A (en) | Preparation method and application of persimmon oligomeric proanthocyanidins |